Luke Evnin Sells 80,852 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 80,852 shares of the company’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $0.48, for a total value of $38,808.96. Following the completion of the sale, the director owned 682,833 shares in the company, valued at $327,759.84. This represents a 10.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $14,650.20.
• On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total value of $12,741.08.
• On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total value of $31,936.50.
• On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $39,341.25.
• On Thursday, May 21st, Luke Evnin sold 36,387 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total value of $15,282.54.
• On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.43, for a total value of $36,934.85.
• On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $28,336.50.
• On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.50, for a total value of $11,092.00.
• On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $43,446.40.
• On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total value of $22,745.16.

Werewolf Therapeutics Trading Down 1.3%

Werewolf Therapeutics stock opened at $0.45 on Friday. The firm has a market capitalization of $21.87 million, a P/E ratio of -0.36 and a beta of 0.41. The stock has a fifty day moving average price of $0.74 and a 200 day moving average price of $0.75. Werewolf Therapeutics, Inc. has a 52 week low of $0.40 and a 52 week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, equities analysts predict that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in HOWL. Regal Investment Advisors LLC increased its stake in Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. increased its stake in Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares during the last quarter. Qube Research & Technologies Ltd acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at about $48,000. AQR Capital Management LLC acquired a new stake in shares of Werewolf Therapeutics in the first quarter valued at about $79,000. Finally, Bridgeway Capital Management LLC grew its stake in shares of Werewolf Therapeutics by 157.7% in the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after buying an additional 62,414 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen lowered Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.